Abstract
The electrocardiographic effects of clovoxamine, an antidepressant that inhibits the neuronal uptake of both noradrenaline and 5-hydroxytryptamine, have been studied. High speed electrocardiograms were recorded on 28 patients with depressive illness before and after 4 weeks treatment with either clovoxamine or placebo. No patient had clinical evidence of cardiovascular disease. The ECG measurements were carried out blind to patient, treatment and treatment interval. No statistically significant changes in the sinus cycle length, PR, QRS and QTc intervals, or T-wave height were found after treatment with active drug or placebo, showing that clovoxamine has no clinically important effects on the ECG when given in therapeutic doses to patients free from serious physical disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
